Potential conflict of interest: Nothing to report.
Article first published online: 4 OCT 2012
Copyright © 2012 American Association for the Study of Liver Diseases
Volume 56, Issue 4, pages 1231–1239, October 2012
How to Cite
Matsumura, T., Kato, T., Sugiyama, N., Tasaka-Fujita, M., Murayama, A., Masaki, T., Wakita, T. and Imawari, M. (2012), 25-hydroxyvitamin D3 suppresses hepatitis C virus production. Hepatology, 56: 1231–1239. doi: 10.1002/hep.25763
T. Matsumura and M. Imawari were partly supported by Chugai Pharmaceutical Co. Ltd. (Tokyo, Japan).
- Issue published online: 4 OCT 2012
- Article first published online: 4 OCT 2012
- Accepted manuscript online: 6 APR 2012 06:57AM EST
- Manuscript Accepted: 29 MAR 2012
- Manuscript Received: 6 DEC 2011
- Japan Society for the Promotion of Science, the Ministry of Health, Labor and Welfare of Japan
- Ministry of Education, Culture, Sports, Science and Technology, and the Research on Health Sciences Focusing on Drug Innovation from the Japan Health Sciences Foundation
Additional Supporting Information may be found in the online version of this article.
|HEP_25763_sm_SuppFig1.tif||170K||Supplementary Figure 1. Anti-HCV effects and cytotoxicity of 25(OH)D3 at high concentrations. HuH-7 cells were treated with indicated concentrations of 25(OH)D3 followed by inoculation with HCVcc. HCV production was assessed by measuring the HCV core Ag (A). HCV core Ag levels in culture medium and cell lysates are indicated by open and closed bars respectively. Cell viability was also assessed by the WST-8 assay after treatment with indicated concentrations of 25(OH)D3 (B). Results are shown as means ± SD of the percent of the control.|
|HEP_25763_sm_SuppFig2.tif||183K||Supplementary Figure 2. ISG induction by 25(OH)D3 treatment. To assess the effects of 25(OH)D3 on IFN signaling, the expression of MxA (A) and OAS (B) mRNA with or without interferon treatment were measured by TaqMan Gene Expression Assay. Results are shown as means log fold increase ± SD.|
|HEP_25763_sm_SuppFig3.tif||176K||Supplementary Figure 3. Anti-HCV effects of 25(OH)D3 in multiple HCV strains other than JFH-1. Anti-HCV effects of 25(OH)D3 on J6/JFH-1, H77S.2, and JFH-1/V2440L. Infectivity titers in culture medium and cell lysates were measured after a 3-day treatment. Results are shown as means ± SD of the percentage of untreated. *p < 0.05 compared with untreated.|
|HEP_25763_sm_SuppFig4.tif||207K||Supporting Information Figure 4. Supplementary Figure 4. Production and anti-HCV effect of 1,25(OH)2D3 in HuH-7 cells. (A) Minimal conversion of 25(OH)D3 to 1,25(OH)2D3 in HuH-7 cells. HuH-7 cells were treated with 25(OH)D3 at various concentrations (0.5, 1.0, 2.0 and 5.0 μM), and production of 1,25(OH)2D3 was measured in the medium. Results are shown as means ± SD. (B) No anti-HCV effect of 1,25(OH)2D3 at low concentrations. Treatment with 1,25(OH)2D3 at concentrations of 1.0 to 0.001 μM, causes no effects on HCV core Ag levels measured in culture medium (open bar) and cell lysates (closed bar). Results are shown as means ± SD of the percentage of ethanol.|
|HEP_25763_sm_SuppTab1.doc||36K||Supporting Information Table 1.|
|HEP_25763_sm_SuppTab2.doc||32K||Supporting Information Table 2.|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.